Damora Therapeutics, Inc. (DMRA) stock
DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
$22.98+0.42 (+1.86%)
Close on Nov 18, 2026Market cap $1.42BP/E 5.8Yield 0.00%
Damora Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Damora Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$304.36M. For fiscal 2025 it was -$210.87M. The highest annual figure on record is $38.97M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$210.87M | – |
| FY2024 | Dec 31, 2024 | -$22.26M | – |
| FY2023 | Dec 31, 2023 | -$39.91M | – |
| FY2022 | Dec 31, 2022 | -$61.21M | – |
| FY2021 | Dec 31, 2021 | -$52.23M | – |
| FY2020 | Dec 31, 2020 | -$33.64M | -186.3% |
| FY2019 | Dec 31, 2019 | $38.97M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$36.86M | – |
| Q2 FY2026 | Jun 30, 2026 | -$34.99M | – |
| Q1 FY2026 | Mar 31, 2026 | -$30.81M | – |
| Q4 FY2025 | Dec 31, 2025 | -$201.70M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.16M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.42M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.60M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.10M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.84M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.58M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.74M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.67M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.58M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.16M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.49M | – |
| Q4 FY2022 | Dec 31, 2022 | -$13.53M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.12M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.94M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.47M | – |
| Q3 FY2021 | Sep 30, 2021 | -$12.94M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.27M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.55M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.30M | -145.5% |
| Q3 FY2020 | Sep 30, 2020 | -$10.17M | -310.7% |
| Q2 FY2020 | Jun 30, 2020 | -$6.34M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.83M | – |
| Q4 FY2019 | Dec 31, 2019 | $24.85M | – |
| Q3 FY2019 | Sep 30, 2019 | $4.83M | – |
See a number that looks wrong?